Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

1.570 +0.100 (+6.80%)
Streaming Delayed Price Updated: 2:51 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 304,886
Open 1.470
Bid (Size) 1.550 (600)
Ask (Size) 1.580 (100)
Prev. Close 1.470
Today's Range 1.470 - 1.600
52wk Range 1.300 - 52.50
Shares Outstanding 15,859,280
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
Pre-production, Engineering Run and GMP Manufacture of PRP in 2026 
From Propanc Biopharma, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill

Performance

YTD
-89.0%
-89.0%
1 Month
-13.7%
-13.7%
3 Month
-38.6%
-38.6%
6 Month
-89.3%
-89.3%
1 Year
-96.6%
-96.6%

More News

Read More
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are the most active in today's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
From Rosen Law Firm
Via Business Wire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
From Propanc Biopharma, Inc.
Via GlobeNewswire
Top movers in Thursday's session ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?
Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
What is the current price of Propanc Biopharma, Inc. - Common Stock?
The current price of Propanc Biopharma, Inc. - Common Stock is 1.570
When was Propanc Biopharma, Inc. - Common Stock last traded?
The last trade of Propanc Biopharma, Inc. - Common Stock was at 06/29/26 02:51 PM ET
What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
The market capitalization of Propanc Biopharma, Inc. - Common Stock is 24.90M
How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
Propanc Biopharma, Inc. - Common Stock has 25M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.